AbbVie Inc. $ABBV Shares Newly Acquired by B.A. Schrock Wealth Management Inc.

Key Points

• B.A. Schrock Wealth Management acquired 33,286 AbbVie shares worth approximately $8.65 million, making ABBV its fifth-largest holding and representing 2.9% of its portfolio. Institutional investors collectively own 70.23% of the company.
• AbbVie exceeded quarterly earnings and revenue expectations, reporting $3.65 in EPS and $16.99 billion in revenue, up 10.2% year over year. Analysts maintain a broadly positive outlook, with a “Moderate Buy” consensus and an average price target of $277.18.
• AbbVie declared a quarterly dividend of $1.73 per share, equivalent to a 2.4% annual yield. Growth optimism centers on SKYRIZI, RINVOQ and Vraylar, though elevated valuation and mixed peer comparisons present potential risks.

B.A. Schrock Wealth Management Inc. acquired a new position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 33,286 shares of the company's stock, valued at approximately $8,652,000. AbbVie comprises about 2.9% of B.A. Schrock Wealth Management Inc.'s investment portfolio, making the stock its 5th largest holding.

Several other hedge funds have also recently added to or reduced their stakes in the business. Corient Private Wealth LP bought a new position in AbbVie in the 2nd quarter worth approximately $559,736,000. Legal & General Group Plc acquired a new position in shares of AbbVie during the second quarter worth approximately $2,905,952,000. Jupiter Topco LLC acquired a new position in shares of AbbVie during the second quarter worth approximately $1,560,354,000. Diamant Asset Management Inc. boosted its position in shares of AbbVie by 21,649.0% in the first quarter. Diamant Asset Management Inc. now owns 3,671,231 shares of the company's stock valued at $798,456,000 after acquiring an additional 3,654,351 shares during the period. Finally, Canada Pension Plan Investment Board bought a new stake in shares of AbbVie in the second quarter valued at approximately $817,473,000. Institutional investors own 70.23% of the company's stock.

AbbVie Stock Performance

NYSE:ABBV opened at $283.58 on Thursday. The company has a 50-day moving average of $261.16 and a 200-day moving average of $238.38. The company has a market capitalization of $501.03 billion, a price-to-earnings ratio of 80.11, a PEG ratio of 1.25 and a beta of 0.24. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $285.40.

AbbVie (NYSE:ABBV - Get Free Report) last issued its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm's revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the business earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Sell-side analysts forecast that AbbVie Inc. will post 13.95 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be paid a dividend of $1.73 per share. The ex-dividend date is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.4%. AbbVie's dividend payout ratio (DPR) is currently 195.48%.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on ABBV shares. Cantor Fitzgerald raised their price objective on shares of AbbVie from $285.00 to $290.00 and gave the stock an "overweight" rating in a research note on Thursday, October 8th. Leerink Partners boosted their target price on shares of AbbVie from $245.00 to $279.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 5th. Rothschild & Co Redburn upped their target price on shares of AbbVie from $284.00 to $285.00 and gave the company a "buy" rating in a research note on Tuesday, August 4th. Barclays upped their target price on shares of AbbVie from $275.00 to $300.00 and gave the company an "overweight" rating in a research note on Wednesday, July 29th. Finally, Erste Group Bank raised shares of AbbVie from a "hold" rating to a "buy" rating in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $277.18.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares of the company's stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.06% of the company's stock.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive SKYRIZI Crohn’s disease data: Phase 3 AFFIRM results showed that subcutaneous SKYRIZI produced meaningful clinical and endoscopic benefits versus placebo, with a safety profile consistent with the established treatment. The data could support regulatory review of a more convenient induction option and strengthen AbbVie’s post-Humira growth franchise. Did SKYRIZI’s Subcutaneous Crohn’s Data Just Shift AbbVie’s Investment Narrative?
• Positive Sentiment: Analyst and earnings optimism: RBC reaffirmed an “outperform” rating and cited potential third-quarter strength from RINVOQ, SKYRIZI, and Vraylar. Erste Group also raised its FY2027 EPS estimate to $16.34 from $16.19 while maintaining a “Buy” rating. Investors are looking ahead to AbbVie’s October 30 earnings report. AbbVie Poised for Q3 Top-Line Beat
• Positive Sentiment: Broad healthcare rally and options activity: Pharmaceutical stocks rallied broadly, supporting ABBV. Investors also purchased 86,296 AbbVie call options, approximately 445% above typical call volume, indicating elevated bullish positioning, although options activity alone does not guarantee further gains. Lilly, Merck, AbbVie Stocks Surge
• Neutral Sentiment: Mixed comparative view: A Zacks analysis argued that Sanofi currently offers a more attractive combination of valuation, outlook, and Dupixent growth, suggesting AbbVie’s strong recent performance has left less valuation upside relative to some peers. Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?
• Negative Sentiment: Valuation and conflicting market reaction: One report characterized ABBV as trading above estimated fair value, while another described an initial decline following the new SKYRIZI data. The conflicting reactions highlight execution, regulatory, and valuation risks despite the data’s long-term potential. A Look at AbbVie After a Decline

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women's health.

The company's products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.